The 11th International AIDS Society Conference on HIV Science

Key studies to be presented at the 11th IAS Conference on HIV Science, from International Co-Chair and IAS President, Dr. Adeeba Kamarulzaman

Adeeba Kamarulzaman, MBBS, FRACP, FASc Released: July 19, 2021

Not sure how to interpret conflicting results in studies of HIV and SARS-CoV-2 coinfection? Dr. Daniel R. Kuritzkes discusses new results of studies of people with HIV and COVID-19, presented at IAS 2021.

Daniel R. Kuritzkes, MD Released: August 20, 2021

Listen to expert insights from Babafemi Taiwo, MBBS, on updates from IAS 2021, including new data on COVID-19 and HIV, 2-drug ART, long-acting injectable ART, investigational agents, and new therapies for multidrug-resistant tuberculosis.

Babafemi Taiwo, MBBS Released: August 19, 2021

Hear insights from Jennifer Cocohoba, PharmD, and Jason Schafer, PharmD, MPH, on exciting new data from IAS 2021, including 2-drug regimens for ART, long-acting ART, and novel antiretrovirals, and learn how these new data influence the role of the pharmacist in caring for patients with HIV.

Jennifer Cocohoba, PharmD Jason Schafer, PharmD, MPH Released: August 23, 2021

Read expert faculty members’ summaries of key studies from this important annual conference, including new data on the following hot topics: HIV PrEP; 2-drug regimen ART; ART in children and adolescents; long-acting ART; investigational ART; treatment strategies for cryptococcal meningitis and drug resistant tuberculosis; and COVID-19 outcomes in people with HIV.

Daniel R. Kuritzkes, MD Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: August 5, 2021

Hear unique insights from CCO’s expert faculty, Dr. Chloe Orkin, as she presents her insights on some of the most clinically relevant new data presented at IAS 2021, including results from studies on HIV and COVID-19 outcomes; virologic and metabolic outcomes of DTG/3TC; long-acting CAB + RPV for ART in treatment-naive PWH; investigational antiretroviral agents, lenacapavir and islatravir; and alternative dosing of BPaL for MDR-TB.

Chloe Orkin, MBChB, FRCP, MD Released: August 9, 2021

Hear unique insights from CCO’s expert faculty, Dr. Daniel Kuritzkes, as he presents his insights on some of the most clinically relevant new data presented at IAS 2021, including results from studies on HIV and COVID-19 outcomes; virologic and metabolic outcomes of DTG/3TC; long-acting CAB + RPV for ART in treatment-naive PWH; investigational antiretroviral agents, lenacapavir and islatravir; and alternative dosing of BPaL for MDR-TB.

Daniel R. Kuritzkes, MD Released: August 9, 2021

Hear unique insights from CCO’s expert faculty, Dr. Babafemi Taiwo, as he presents his insights on some of the most clinically relevant new data presented at IAS 2021, including results from studies on HIV and COVID-19 outcomes; virologic and metabolic outcomes of DTG/3TC; long-acting CAB + RPV for ART in treatment-naive PWH; investigational antiretroviral agents, lenacapavir and islatravir; and alternative dosing of BPaL for MDR-TB.

Babafemi Taiwo, MBBS Released: August 10, 2021

Leia os resumos feitos pelos membros especialistas do painel sobre os principais estudos desta importante conferência anual, incluindo novos dados sobre os seguintes temas atuais: PrEP do VIH; tratamento ART com dois medicamentos combinados; ART em crianças e adolescentes; ART de longa duração; ART experimental; estratégias de tratamento para a meningite criptocócica e para a tuberculose resistente a medicamentos; e resultados da COVID-19 em pacientes com VIH.

Daniel R. Kuritzkes, MD Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: August 30, 2021

Podrá leer resúmenes de miembros expertos del panel sobre los estudios principales de esta importante conferencia anual, incluidos nuevos datos sobre los siguientes temas candentes: PrEP del VIH; régimen TAR de 2 fármacos, TAR en niños y adolescentes, TAR de larga duración, TAR experimental, estrategias de tratamiento para la meningitis criptocócica y la tuberculosis resistente a los fármacos, y resultados de la COVID-19 en pacientes con VIH.

Daniel R. Kuritzkes, MD Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: August 30, 2021

Read my take on new Eastern European studies from IAS 2021 on improving HIV services, innovative methods for HIV prevention during COVID-19, outreach programs, and more.

Deniz Gökengin, MD Released: September 1, 2021

Here’s why I think we can be reassured by the multinational SALSA study findings, which demonstrated noninferior virologic efficacy of switching vs continuing various 3-drug or 4-drug regimens.

Josep M. Llibre, MD, PhD Released: August 23, 2021

My key takeaways on data presented from 2 prevention studies at IAS 2021, including Internet-based survey results about long-acting injectable PrEP among American MSM and oral monthly islatravir.

Darrell H. S. Tan, MD, FRCPC, PhD Released: August 18, 2021

In this commentary, find out why I think studies on ARV-associated weight gain and long-acting ART are important for the treatment landscape in Australia.

Don Smith, MD Released: August 18, 2021

My insights from Latin America on the results of the AMBITION-cm trial using single, high dose of liposomal Amphotericin B vs standard therapy for cryptococcal meningitis.

Pedro Cahn, MD, PhD Released: August 20, 2021

Could liposomal amphotericin B (LAmB) be useful in patients with elevated intracranial pressure (ICP)? Here are my thoughts based on the AMBITION-cm study presented at IAS.

Chien-Ching Hung, MD, PhD Released: September 2, 2021

My perspectives on how LA CAB/RPV and liposomal amphotericin B have unique considerations for people with HIV in Africa.

Babafemi Taiwo, MBBS Released: September 17, 2021